Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT ®, a three-fold reduction from 67.4 percent historically seen with standard IRR management ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
Reducing pembrolizumab infusions from 30 minutes to 10 minutes could be a safe alternative for patients and open hundreds of ...
Briumvi (ublituximab-xiiy) is a prescription drug used to treat certain types of multiple sclerosis (MS). Briumvi can cause side effects that range from mild to serious. Examples include upper ...
Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from ...
Leqembi’s common side effects include headache and infusion reactions, which may be manageable with guidance from your doctor. Serious side effects, including ARIA (amyloid-related imaging ...
Fabrazyme (agalsidase beta) is a brand-name intravenous (IV) infusion that’s prescribed for Fabry disease in adults and certain children. As with other drugs, Fabrazyme can cause side effects, such as ...
Avsola (infliximab-axxq) is a brand-name IV infusion that’s prescribed for certain autoimmune diseases, including rheumatoid arthritis, ulcerative colitis, and psoriasis. As with other drugs, Avsola ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results